Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Clin Cancer Res. 2011 Feb 15;17(7):1807–1814. doi: 10.1158/1078-0432.CCR-10-1276

Figure 1. Clonogenic Assays.

Figure 1

a) hGRM1-positive C8161 human melanoma cells were treated with riluzole at 25µM for 24 hrs followed by escalating doses of ionizing radiation (IR). At 2Gy, there was a 48% reduction (0.78 ± 0.100 vs. 0.30± 0.089, p= .010) in cell survival in riluzole-treated cells versus non-treated cells. At 4 Gy, there was a 19% reduction (0.30 ± 0.121 vs. 0.11 ± 0.055, p= 0.048) in cell survival in riluzole-treated cells vs. non-treated cells. No differences were seen at 6 and 8 Gy. b) hGRM1-positive UACC903 human melanoma cells were treated with riluzole at 25 uM for 24 hours followed by escalating doses of IR. At 2 Gy, surviving fraction (SF) 0.473 ± 0.020 vs 0.233 ± 0.056 (p=0.002). At 4 Gy, SF 0.078 ± 0.010 vs 0.040 ± 0.020 (p=0.046). At 6 Gy, SF 0.013 ± 0.003 vs 0.008 ± 0.003 (p=0.110). At 8 Gy, SF 0.001 ± 0.001 vs 0.001 ± 0.001 (p=0.930). c) hGRM1-negative UACC930 human melanoma cells were treated with riluzole at 25µM for 24 hrs followed by escalating doses of IR. There was no difference between treated and untreated control UACC930 cells (p=NS).